10/06/2020
F2G’s olorofim receives both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP designation for multiple fungal infections F2G Ltd, a UK- and Austria-based biotech developing novel therapies for life-threatening systemic fungal infections,...
29/05/2020
Orphazyme initiates rolling submission of New Drug Application for arimoclomol with US FDA in Niemann-Pick disease Type C Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan...
22/05/2020
Orphazyme’s arimoclomol receives US Fast Track Designation in Amyotrophic Lateral Sclerosis Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announces that the Company...
14/05/2020
VAXIMM Announces First Results from Phase I/II Trial in Progressive Glioblastoma with Oral T-cell Immunotherapy VXM01 in Combination with PD-L1 Inhibitor Avelumab to be Presented at ASCO20 Virtual 14 May 2020, VAXIMM AG, a Swiss/German biotech company focused on...
16/04/2020
Patent for Oncoral approved in Japan Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia”) today announced that the patent application for Oncoral has been approved in Japan. The approval in Japan adds to the already obtained patents in the US and a selected number of...
We use cookies on the website sunstone.eu in order to generate statistics and to maximize user-friendliness and improve functionality. By using our website, you consent to our use of cookies. Click on cookie settings below if you wish to disable cookies. Or you can read more about what cookies are, how we use them and how you disable cookies Here.
Cookie settingsAccept Privacy & Cookies Policy
Recent Comments